Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Shares moves the most in 11-months on a single day basis. Shares of Century Therapeutics Inc IPSC +20.8% Get Free Report ...
Sarepta price target lowered to $202 from $205 at Needham
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...
Business Insider3d
Piper Sandler Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $182.00. The company’s shares closed ...
Business Insider4d
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy ...
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
bovnews4d
Arrowhead Pharmaceuticals (ARWR) Soars with Strategic Deal: A Transformative Move for the Company
Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...